Zacks Research Analysts Increase Earnings Estimates for ESLA

Estrella Immunopharma, Inc. (NASDAQ:ESLA) – Analysts at Zacks Research lifted their FY2026 earnings per share estimates for Estrella Immunopharma in a report issued on Wednesday, August 26th. Zacks Research analyst D. Bautz now forecasts that the company will earn ($0.25) per share for the year, up from their previous forecast of ($0.29). The consensus estimate for Estrella Immunopharma’s current full-year earnings is ($0.29) per share.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.04.

Separately, Weiss Ratings upgraded Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Estrella Immunopharma has a consensus rating of “Hold” and a consensus target price of $8.00.

Estrella Immunopharma Trading Down 4.6%

ESLA opened at $0.69 on Wednesday. The stock has a market capitalization of $30.08 million, a P/E ratio of -2.88 and a beta of 0.88. Estrella Immunopharma has a 12 month low of $0.63 and a 12 month high of $3.15. The firm’s fifty day simple moving average is $0.81 and its 200 day simple moving average is $1.09.

Hedge Funds Weigh In On Estrella Immunopharma

Several institutional investors and hedge funds have recently modified their holdings of ESLA. Quadrature Capital Ltd bought a new stake in shares of Estrella Immunopharma during the fourth quarter worth approximately $43,000. BlackRock Inc. bought a new stake in shares of Estrella Immunopharma in the second quarter valued at about $54,000. State Street Corp grew its stake in shares of Estrella Immunopharma by 93.5% in the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after acquiring an additional 20,900 shares in the last quarter. XTX Topco Ltd increased its position in Estrella Immunopharma by 376.9% during the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after acquiring an additional 39,099 shares during the period. Finally, Marshall Wace LLP bought a new position in Estrella Immunopharma during the fourth quarter worth about $88,000. 0.35% of the stock is currently owned by institutional investors and hedge funds.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.